Acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome: prevalence, main characteristics, and outcomes in a Brazilian center

Abstract

Background Progressive multifocal leukoencephalopathy (PML) - immune reconstitution inflammatory syndrome (IRIS) in people living with HIV/AIDS (PLWHA) has been rarely described in low- and middle-income countries.

Objective To describe the prevalence of PML-IRIS among PLWHA with PML and its main features in a tertiary hospital in Brazil.

Methods We performed a retrospective cohort study. We included PLWHA with PML-IRIS patients admitted at Instituto de Infectologia Emílio Ribas, São Paulo, Brazil, between 2011 and 2021. We retrieved information on neurological manifestations, neuroimaging findings, treatments, and outcomes.

Results We identified 11 (11.8%) PML-IRIS cases among 93 patients with definite PML. Eight (73%) cases were men and had a median (IQR) age of 41 (27–50) years. Seven (63.6%) patients developed unmasking PML-IRIS and 4 (36.4%) had paradoxical PML-IRIS. The median (IQR) time from initiation of combined antiretroviral therapy (cART) to IRIS diagnosis was 49 (30–70) days. Ten (90.9%) patients received corticosteroids. There were 4 (36%) in-hospital deaths and 3 were associated with hospital-acquired pneumonia. Among the 7 (64%) patients who survived, 5 (71.5%) had sequelae at discharge. One year after the PML-IRIS diagnosis, 6 (54.5%) patients were alive.

Conclusion The prevalence of PML-IRIS was 11.8%. Most patients had unmasking PML-IRIS. In-hospital mortality and morbidity were high. One-year survival was similar to that described in some high-income countries.

Resumo

Antecedentes A síndrome inflamatória de reconstituição imune (SIRI) da leucoencefalopatia multifocal progressiva (LEMP) em pessoas vivendo com HIV/Aids (PVHA) foi raramente descrita em países de baixa e média renda.

Objetivo Descrever a prevalência da SIRI-LEMP- em PVHA com LEMP e suas principais características em um hospital no Brasil.

Métodos Foi realizado um estudo de coorte retrospectivo. Incluímos PVHA com SIRI-LEMP admitidos no Instituto de Infectologia Emílio Ribas, São Paulo, Brasil, entre 2011 e 2021. Recuperamos informações sobre manifestações neurológicas, neuroimagem, tratamento e desfecho.

Resultados Identificamos 11 (11,8%) casos de SIRI-LEMP entre 93 pacientes com LEMP definitiva. Oito (73%) casos eram homens e a mediana de idade (amplitude interquartile - AIQ) foi de 41 (27–50) anos. Sete (63,6%) pacientes desenvolveram SIRI-LEMP “desmascarada” e 4 (36,4%) casos apresentaram SIRI-LEMP “paradoxal”. A mediana de tempo (AIQ) desde o início da terapia antirretroviral combinada (cART) até o diagnóstico de SIRI foi de 49 (30–70) dias. Dez (90,9%) pacientes receberam corticoide. Houve 4 (36%) óbitos intra-hospitalares e 3 foram associados à pneumonia hospitalar. Dos 7 (64%) pacientes que sobreviveram, 5 (71,5%) ficaram com sequelas na alta. Um ano após o diagnóstico de SIRI-LEMP, 6 (54,5%) pacientes estavam vivos.

Conclusão A prevalência de SIRI-LEMP foi de 11,8%. A maioria dos pacientes apresentava SIRI-LEMP “desmascarada”. A mortalidade e morbidade hospitalar foram altas. A sobrevida em 1 ano foi semelhante à descrita em alguns países de alta renda.

Keywords

Leukoencephalopathy, Progressive Multifocal - Immune Reconstitution Inflammatory Syndrome - Epidemiology - HIV - Brazil

Palavras-chave

Leucoencefalopatia Multifocal Progressiva - Síndrome Inflamatória da Reconstituição Imune - Epidemiologia - HIV - Brasil

Author's Contributions

MNS: conceptualization, data curation, formal analysis, investigation, methodology, resources, software, writing review, and editing; RF: data curation, investigation, writing review and editing, software; ACM: writing review and editing; RMNM: data curation, formal analysis, writing review and editing, software; RAF: conceptualization, data curation, investigation, writing review and editing, software; JEV: conceptualization, formal analysis, methodology, project administration, resources, supervision, validation, writing-original draft, writing review, and editing.

Publication History

Received: 10 March 2023

Accepted: 07 June 2023

Article published online:
29 October 2023

• References

• 1 Major EO. History and current concepts in the pathogenesis of PML. Cleve Clin J Med 2011; 78 (Suppl. 02) S3-S7
• 2 Ferenczy MW, Marshall LJ, Nelson CD. et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25 (03) 471-506
• 3 Åström KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81 (01) 93-111
• 4 Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1 (7712) 1257-1260
• 5 Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2 (02) 299-313
• 6 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9 (04) 425-437
• 7 Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4 (01) 59-68
• 8 d'Arminio Monforte A, Cinque P, Mocroft A. et al; EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55 (03) 320-328
• 9 Wyen C, Hoffmann C, Schmeisser N. et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37 (02) 1263-1268
• 10 Antinori A, Cingolani A, Lorenzini P. et al; Italian Registry Investigative Neuro AIDS Study Group. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Suppl. 01) 47-53
• 11 Engsig FN, Hansen AB, Omland LH. et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199 (01) 77-83
• 12 Cinque P, Bossolasco S, Brambilla AM. et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl. 01) 73-80
• 13 Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57 (02) 167-170
• 14 Fournier A, Martin-Blondel G, Lechapt-Zalcman E. et al. Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review. Front Immunol 2017; 8: 577
• 15 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (04) 251-261
• 16 Vidal JE, Penalva de Oliveira AC, Fink MC, Pannuti CS, Trujillo JR. Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in São Paulo, Brazil. Rev Inst Med Trop São Paulo 2008; 50 (04) 209-212
• 17 Guevara-Silva EA, Ramírez-Crescencio MA, Soto-Hernández JL, Cárdenas G. Central nervous system immune reconstitution inflammatory syndrome in AIDS: experience of a Mexican neurological centre. Clin Neurol Neurosurg 2012; 114 (07) 852-861
• 18 Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72 (17) 1458-1464
• 19 Berger JR, Aksamit AJ, Clifford DB. et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80 (15) 1430-1438
• 20 Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ. et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol 2016; 23 (05) 919-925
• 21 Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) 2015; 7: 49-64
• 22 Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep 2013; 15 (06) 583-593
• 23 Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 2021; 17 (01) 37-51
• 24 Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC. et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81 (03) 213-227
• 25 French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18 (12) 1615-1627
• 26 Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006; 2 (10) 557-565
• 27 Breton G, Duval X, Estellat C. et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39 (11) 1709-1712
• 28 Shelburne SA, Visnegarwala F, Darcourt J. et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19 (04) 399-406
• 29 Mateen FJ, Nath A. Central nervous system-immune reconstitution inflammatory syndrome in resource-limited settings: current burden and future needs. AIDS 2012; 26 (15) 1851-1855
• 30 Navis A, Siddiqi O, Chishimba L, Zimba S, Morgello S, Birbeck GL. Immune reconstitution inflammatory syndrome in the central nervous system: Limitations for diagnosis in resource limited settings. J Neurol Sci 2020; 416: 117042
• 31 Piza F, Fink MC, Nogueira GS, Pannuti CS, Oliveira AC, Vidal JE. JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome. Braz J Infect Dis 2012; 16 (02) 153-156
• 32 Lima MA, Silva MTT, Afonso LA, Vaz BJP. Post-cART progressive multifocal leukoencephalopathy era in a Brazilian center. J Neurol Sci 2017; 381: 321-324
• 33 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43 (08) 4175-4177
• 34 Bowen L, Nath A, Smith B. CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol 2018; 152: 167-176
• 35 Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?. J Neurovirol 2003; 9 (Suppl. 01) 25-31
• 36 Berger JR. Steroids for PML-IRIS: a double-edged sword?. Neurology 2009; 72 (17) 1454-1455
• 37 Tassie JM, Gasnault J, Bentata M. et al; Clinical Epidemiology Group. French Hospital Database on HIV. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 1999; 13 (14) 1881-1887
• 38 Grabar S, Lanoy E, Allavena C. et al; Clinical Epidemiology Group of the French Hospital Database on HIV. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9 (04) 246-256
• 39 Khanna N, Elzi L, Mueller NJ. et al; Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48 (10) 1459-1466
• 40 Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9 (10) 625-636
• 41 Lanoy E, Guiguet M, Bentata M. et al; FHDH-ANRS CO4. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011; 76 (07) 644-651